Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-346

Speaking as an utter noob, seeing they are getting potentially better immunogenicity via injections in different arms (meaning more antibodies being educated at the site of the injections b4 they move away & educate other antibodies), I was wondering why they are doing intradermal injections rather than intramuscular, and this might sound even sillier, would it matter if they did the injections in areas closer to the normal sites of outbreaks i.e. near the genitals... so a injection in the ventrogluteal area (fleshy part below the hips). Also, weight/dosing is not normally an issue with vaccines, but its a pity they didnt break out the results according to weight. I was also fascinated by WP's talk of looking into complementary methods to improve efficacy. Would this mean they'd need to test this aspect via another Phase I trial? I didnt think they could bolt on new things (other than dosing) into a mid stage clinical phase candidate without re-doing safety tests.... I'm sure Ian is all over this....